UTI Knowledge Center
Antibiotic Spotlight

Linezolid

Emery Haley, PhD, Scientific Writing Specialist

Linezolid

Find the Latest FDA-Approved Labelling Information Here: Drugs@FDA Online Database

Administrative Routes

Oral (PO) or Parenteral [intravenous infusion (IV)]

Other Names

Zyvox

Bacteriostatic or Bactericidal

Bacteriostatic [1]

Antibiotic Class

Oxazolidinone

Mechanisms of Action

The drug binds to the 50S ribosomal subunit of bacterial ribosomes. Binding to bacterial ribosomes blocks bacterial cells from synthesizing proteins required for growth.

WHO AWaRe Classification

Reserve [2]

Empiric Use Recommendations

No published guidance

Indication(s) Relevant to UTI

On label for treatment of specific gram-positive infections, including those caused by vancomycin-resistant Enterococcus faecium.

Checkmarks

CLSI and/or FDA documents support the efficacy of this antibiotic against the following organisms from the Guidance® UTI test: Alloscardovia omnicolens, Aerococcus urinae, Corynebacterium riegelii, Coagulase-negative Staphylococci, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, and Viridans Group Streptococci.  

Published primary literature supports the efficacy of this antibiotic against the following organisms from the Guidance® UTI test:   Alloscardovia omnicolens ​[3] and Actinotignum schaalii [4]

About the Author

Dr. Emery Haley is a scientific writing specialist with over ten years of experience in translational cell and molecular biology. As both a former laboratory scientist and an experienced science communicator, Dr. Haley is passionate about making complex research clear, approachable, and relevant. Their work has been published in over 10 papers and focuses on bridging the gap between the lab and real-world patient care to help drive better health outcomes.

Ready to see what better diagnostics can do for your practice?

Talk to a Pathnostics representative about Guidance® UTI and our other tests.

Talk to a Rep See Our Tests
References
  1. Ishak, A.; Mazonakis, N.; Spernovasilis, N.; Akinosoglou, K.; Tsioutis, C. Bactericidal versus Bacteriostatic Antibacterials: Clinical Significance, Differences and Synergistic Potential in Clinical Practice. J. Antimicrob. Chemother. 2024, 80, 1–17, doi:10.1093/jac/dkae380
  2. AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use, 2023 Available online: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04 (accessed on 6 February 2025).
  3. Isnard, C.; Lienhard, R.; Reissier, S.; Rodriguez, S.; Krähenbühl, J.; Liassine, N.; Guérin, F.; Cattoir, V. In Vitro Antimicrobial Susceptibility of Alloscardovia Omnicolens and Molecular Mechanisms of Acquired Resistance. Diagnostic Microbiology and Infectious Disease 2016, 84, 227–229, doi:10.1016/j.diagmicrobio.2015.08.009.
  4. Sahuquillo-Arce, J.M.; Suárez-Urquiza, P.; Hernández-Cabezas, A.; Tofan, L.; Chouman-Arcas, R.; García-Hita, M.; Sabalza-Baztán, O.; Sellés-Sánchez, A.; Lozano-Rodríguez, N.; Martí-Cuñat, J.; et al. Actinotignum Schaalii Infection: Challenges in Diagnosis and Treatment. Heliyon 2024, 10, e28589, doi:10.1016/j.heliyon.2024.e28589.